Programmatic learnings on advance community-based distribution of misoprostol for prevention of postpartum hemorrhage: experience of Aweil East County, South Sudan
This paper synthesizes programmatic learnings from a pilot in South Sudan demonstrating that while community-based advance distribution of misoprostol achieved high coverage and understanding, its effectiveness is currently hindered by incorrect timing of use, supply chain packaging issues, and stakeholder anxieties regarding misuse, highlighting the urgent need for targeted investments to scale this lifesaving intervention for mothers in low-resource settings.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In many parts of the world, the most dangerous moment for a mother is not the birth itself, but the time immediately after. When a baby is born, the mother's body must contract tightly to stop the bleeding from the placenta, the organ that fed the baby during pregnancy. If these contractions are too weak, the mother can lose a fatal amount of blood in a matter of hours. This condition, known as postpartum hemorrhage, remains the leading cause of maternal death globally. In wealthy nations, this risk is managed in hospitals with powerful intravenous medications and skilled staff. But in remote, rural areas where hospitals are days away or inaccessible due to floods and conflict, mothers often give birth at home with no medical help nearby. For these women, a simple, heat-stable pill called misoprostol offers a potential lifeline. It is a medication that can be taken by mouth to trigger the necessary contractions, but its use in community settings is complicated by fears that it could be misused for other purposes, such as ending a pregnancy, and by the logistical difficulty of getting the right dose to the right person at the exact right moment.
In the scattered, flood-prone villages of Aweil East County in South Sudan, the International Rescue Committee set out to test whether this life-saving pill could be safely and effectively distributed to women before they gave birth. Working with a national network of community health workers known as Boma Health Workers, the team piloted a program where these workers visited pregnant women in their homes. The goal was to provide education and a specific package of care, including a supply of misoprostol to be kept at home for use immediately after the baby is born but before the placenta is delivered. The researchers wanted to see if this approach could work in a humanitarian crisis setting, where trust is fragile, literacy is low, and the fear of unintended consequences often outweighs the fear of the disease itself. They gathered data from thousands of women, health workers, and government officials to understand not just if the pills were used, but how they were understood, when they were taken, and what barriers stood in the way of saving more lives.
The program found that the community was ready to accept this intervention. When the health workers explained that the medication was designed to stop heavy bleeding after a baby was born, the vast majority of women understood the purpose. In fact, nearly 70 percent of women in the entire area reported receiving the medication, and among those who received it, almost everyone said they used it. The fear that the community would misuse the drug to end pregnancies did not materialize among the women themselves; in the data collected, there was no evidence of the medication being used for abortion by the recipients. Instead, the primary obstacle was not a lack of trust in the medicine, but a gap in the timing of its use. While the pill is most effective when taken immediately after the baby is born but before the placenta comes out, about 29 percent of women reported taking it after the placenta had already been delivered. At that point, the medication could no longer prevent the most dangerous bleeding, rendering the intervention less effective for a significant portion of the population.
The challenges were not just about timing; they were also about the people delivering the care and the system supporting them. The community health workers, who are often local women with limited formal education, faced a heavy psychological burden. They were deeply afraid that if a woman used the pill incorrectly or if it were misused, the blame would fall on them. This anxiety led some workers to insist on delivering the counseling in front of husbands or family members, and to spend excessive time tracking down empty pill wrappers to prove the medicine had been used. Meanwhile, higher-level government officials and stakeholders expressed deep skepticism about giving such a sensitive drug to community workers. They worried about the low literacy rates and the potential for the drug to be used for abortion, despite the lack of any documented cases of such misuse in the program. This disconnect meant that while the community embraced the solution, the leadership remained hesitant, creating a barrier to scaling the program up to a national level.
Another significant hurdle was the physical supply of the medication itself. The recommended dose for preventing bleeding is three tablets, but the global supply chain only provided the drug in packs of four, intended for different medical uses. To make the program work, the project team had to manually cut the four-tablet packs into three-tablet doses and repackage them with special stickers to guide the users. This process was labor-intensive and created logistical nightmares, as it was difficult to store and account for the leftover single tablets. The researchers noted that this kind of manual repackaging is not a sustainable solution for a large-scale program. They argued that for this life-saving intervention to reach the millions of women who need it, the global supply chain must change to provide the correct three-tablet packaging directly, removing the need for dangerous and time-consuming manual adjustments.
The study concluded that distributing misoprostol in advance to communities is a promising strategy that can save lives in places where hospitals are out of reach. The data showed that when the medicine was available, women took it, and they understood why. However, the program also revealed that simply handing out the pills is not enough. To truly protect mothers, the system must ensure the pills are taken at the precise moment they are needed, which may require better support from birth companions or traditional birth attendants who are present at the delivery. Furthermore, the stigma surrounding the drug and the anxiety of the health workers must be addressed through better training and a shift in how policymakers view community health workers. Finally, the manufacturers and global health organizations must adapt the packaging of the drug to fit the needs of community distribution. Without these changes, the most vulnerable mothers, those living far from hospitals in the most difficult conditions, will remain at risk of a preventable tragedy.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.